HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

GENFLEET-B

32.260

-1.240-3.70%

Volume:1.08M

Turnover:35.02M

Market Cap:11.94B

PE:-4.60

High:34.240

Open:32.980

Low:31.040

Close:33.500

52wk High:52.900

52wk Low:19.600

Shares:370.00M

HK Float Shares:338.00M

Volume Ratio:0.97

T/O Rate:0.32%

Dividend:- -

Dividend Rate:- -

EPS(LYR):-7.009

ROE:--

ROA:-12.49%

PB:5.70

PE(LYR):-4.60

PS:79.35

Loading ...

Overview Company News Filings

GENFLEET-B Shares Surge Following Clinical Trial Acceptance and Positive Analyst Coverage

GENFLEET-B Shares Surge Over 6% Following Clinical Trial Acceptance for Dual-Antibody Therapy

GenFleet GFH375 wins China breakthrough status for KRAS G12D pancreatic cancer therapy

Southwest Securities Initiates Coverage on GENFLEET-B, Recommends Active Monitoring for Its Leading Global Pipeline

GenFleet Therapeutics: All 2026 AGM Proposals Cleared; 80% Backing for Expanded Share-Issue Mandate

Bulletin Express

Genfleet Therapeutics shareholders pass AGM resolutions by poll vote

Stock Track | ...

GENFLEET-B (02595) Clarifies No Connection to Rev Med's Legal Dispute

Stock Track | GenFleet Therapeutics Plummets 11.85% Intraday After Clarification on Patent Disputes

Genfleet Therapeutics (Shanghai) Inc - States Gfh276 Developed on Independent Proprietary Intellectual Property

THOMSON REUTERS

Genfleet Therapeutics (Shanghai) Inc - All Entities, Products or Disputed Matters Referenced in Revmed's Correspondence Entirely Unrelated to Co

THOMSON REUTERS

GenFleet says GFH276 IP independent, not tied to RevMed RAS patent disputes

GENFLEET-B Surges Over 7% in Morning Session as Two GFH375/VS-7375 Preclinical Studies Selected for Late-Breaking Research Abstracts

GENFLEET-B Shares Surge Over 4% in Morning Session on Release of Preclinical Data for Pan-RAS Inhibitor GFH276

Stock Track | Genfleet Therapeutics Soars 5.55% Intraday on Strong Revenue Growth, Buyback Plan, and Breakthrough Therapy Designation

GenFleet Therapeutics to Seek Shareholder Nod for Share Mandates, Governance Revamp at 11 May 2026 AGM

Bulletin Express

GenFleet Therapeutics Schedules 11 May 2026 AGM to Approve 2025 Results, Auditor Re-Appointment and Share Buy-Back Mandate

Bulletin Express

GenFleet Therapeutics Sets 11 May 2026 AGM; Targets 10% Share Buy-back and 20% Issuance Mandates

Bulletin Express

Genfleet Therapeutics announces annual general meeting notice

Genfleet Therapeutics publishes 2025 annual report

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/02595/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"02595","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02595\",,,,,undefined,":{"symbol":"02595","market":"HK","secType":"STK","nameCN":"GENFLEET-B","latestPrice":32.26,"timestamp":1779782902006,"preClose":33.5,"halted":0,"volume":1083955,"delay":0,"changeRate":-0.03701492537313439,"floatShares":338000000,"shares":370000000,"eps":-7.009023658205927,"marketStatus":"Not Yet Opened","change":-1.24,"latestTime":"05-26 16:08:22","open":32.98,"high":34.24,"low":31.04,"amount":35016880,"amplitude":0.095522,"askPrice":32.26,"askSize":200,"bidPrice":32.14,"bidSize":4200,"shortable":3,"etf":0,"ttmEps":-6.193806079508499,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1779845400000},"marketStatusCode":0,"adr":0,"listingDate":1758211200000,"exchange":"SEHK","adjPreClose":33.5,"openAndCloseTimeList":[[1779759000000,1779768000000],[1779771600000,1779782400000]],"volumeRatio":0.967063,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02595\",,,,,undefined,":{"symbol":"02595","floatShares":338000000,"roa":"-12.49%","roe":"--","lyrEps":-7.009024,"volumeRatio":0.967063,"shares":370000000,"dividePrice":0,"high":34.24,"amplitude":0.095522,"preClose":33.5,"low":31.04,"week52Low":19.6,"pbRate":"5.70","psRate":"79.35","week52High":52.9,"institutionHeld":0,"latestPrice":32.26,"committee":0.909091,"eps":-7.009023658205927,"divideRate":0,"volume":1083955,"delay":0,"ttmEps":-6.193806079508499,"open":32.98,"prevYearClose":23.78,"prevWeekClose":33.5,"prevMonthClose":43.14,"prevQuarterClose":33.42,"fiveDayClose":34.44,"twentyDayClose":49.46,"sixtyDayClose":28.92},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/02595\",params:#limit:5,,,undefined,":[{"date":"2026-03-24","symbol":"02595","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1774315800000,"name":null,"time":"","dateTimestamp":1774281600000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"02595\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"02595\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":0.6667,"buy":0.3333,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.6667,"analysts":3,"updateTime":1776268800000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/02595\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"02595","date":"2026-05-22","current":-5.205709,"percent":0.919753,"low":-19.62221,"twenty":-11.098455,"median":-10.138144,"eighty":-8.800358,"high":-5.69787,"avg":-10.419693,"sd":2.620978,"marketCap":12407282105},"quantilePoints":[{"date":"2025-09-19","current":-19.62221,"twenty":-19.62221,"median":-19.62221,"eighty":-19.62221,"marketCap":14538840523},{"date":"2025-09-26","current":-17.850791,"twenty":-18.989349,"median":-18.569255,"eighty":-18.336187,"marketCap":13192012066},{"date":"2025-10-03","current":-19.06699,"twenty":-19.162092,"median":-18.845312,"eighty":-18.417026,"marketCap":14124431767},{"date":"2025-10-10","current":-11.809112,"twenty":-19.045684,"median":-18.645404,"eighty":-16.087956,"marketCap":11948785798},{"date":"2025-10-17","current":-10.861917,"twenty":-19.006201,"median":-18.336187,"eighty":-11.374297,"marketCap":10981832034},{"date":"2025-10-24","current":-9.567304,"twenty":-18.816504,"median":-12.899451,"eighty":-10.554523,"marketCap":9676444452},{"date":"2025-10-31","current":-9.989391,"twenty":-18.681528,"median":-11.762498,"eighty":-10.081819,"marketCap":10118416331},{"date":"2025-11-07","current":-9.878556,"twenty":-18.646705,"median":-10.725216,"eighty":-9.89625,"marketCap":9999899010},{"date":"2025-11-14","current":-11.674836,"twenty":-18.558233,"median":-10.712517,"eighty":-9.936062,"marketCap":11851732160},{"date":"2025-11-21","current":-10.329745,"twenty":-18.396816,"median":-10.725216,"eighty":-10.005136,"marketCap":10481375629},{"date":"2025-11-28","current":-10.423287,"twenty":-18.142029,"median":-10.678396,"eighty":-10.044836,"marketCap":10614707615},{"date":"2025-12-05","current":-10.100425,"twenty":-16.087956,"median":-10.631034,"eighty":-10.044836,"marketCap":10303599646},{"date":"2025-12-12","current":-10.212238,"twenty":-13.008301,"median":-10.584309,"eighty":-10.020393,"marketCap":10436931633},{"date":"2025-12-19","current":-9.790532,"twenty":-12.136764,"median":-10.450758,"eighty":-9.957409,"marketCap":10029528340},{"date":"2025-12-24","current":-8.945585,"twenty":-11.809112,"median":-10.416014,"eighty":-9.900509,"marketCap":9192499756},{"date":"2026-01-02","current":-8.020182,"twenty":-11.73453,"median":-10.320373,"eighty":-9.861601,"marketCap":8273990514},{"date":"2026-01-09","current":-11.588563,"twenty":-11.683046,"median":-10.309663,"eighty":-9.776189,"marketCap":11985064146},{"date":"2026-01-16","current":-11.693807,"twenty":-11.67863,"median":-10.369243,"eighty":-9.793132,"marketCap":12133210798},{"date":"2026-01-23","current":-10.361602,"twenty":-11.605818,"median":-10.329745,"eighty":-9.783265,"marketCap":10740632270},{"date":"2026-01-30","current":-10.919089,"twenty":-11.483053,"median":-10.385171,"eighty":-9.793132,"marketCap":11370255541},{"date":"2026-02-06","current":-11.146899,"twenty":-11.598147,"median":-10.450758,"eighty":-9.8258,"marketCap":11636919514},{"date":"2026-02-13","current":-10.659945,"twenty":-11.483053,"median":-10.58187,"eighty":-9.869606,"marketCap":11192479558},{"date":"2026-02-20","current":-10.145441,"twenty":-11.446311,"median":-10.573435,"eighty":-9.881527,"marketCap":10636929613},{"date":"2026-02-27","current":-9.574146,"twenty":-11.38719,"median":-10.509847,"eighty":-9.836956,"marketCap":10148045662},{"date":"2026-03-06","current":-8.841756,"twenty":-11.29428,"median":-10.416014,"eighty":-9.744297,"marketCap":9296202413},{"date":"2026-03-13","current":-10.316011,"twenty":-11.38719,"median":-10.450758,"eighty":-9.761464,"marketCap":10896186254},{"date":"2026-03-20","current":-10.186272,"twenty":-11.29428,"median":-10.385171,"eighty":-9.744297,"marketCap":10718410272},{"date":"2026-03-27","current":-5.945762,"twenty":-11.270982,"median":-10.329745,"eighty":-9.723416,"marketCap":12081359470},{"date":"2026-04-02","current":-6.621163,"twenty":-11.205287,"median":-10.312136,"eighty":-9.574146,"marketCap":13518381995},{"date":"2026-04-10","current":-7.067323,"twenty":-11.18954,"median":-10.310332,"eighty":-9.547859,"marketCap":14540593893},{"date":"2026-04-17","current":-8.194366,"twenty":-11.170082,"median":-10.271344,"eighty":-9.114302,"marketCap":16866496330},{"date":"2026-04-24","current":-11.736244,"twenty":-11.170082,"median":-10.248784,"eighty":-8.950161,"marketCap":18318333519},{"date":"2026-04-30","current":-10.233962,"twenty":-11.173069,"median":-10.230093,"eighty":-8.995356,"marketCap":15977616418},{"date":"2026-05-08","current":-9.881779,"twenty":-11.158327,"median":-10.186272,"eighty":-9.095725,"marketCap":15481325134},{"date":"2026-05-15","current":-8.422278,"twenty":-11.148553,"median":-10.161068,"eighty":-8.948635,"marketCap":13229496023},{"date":"2026-05-22","current":-7.916926,"twenty":-11.098455,"median":-10.138144,"eighty":-8.800358,"marketCap":12407282105}],"updateTime":1779792921856},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"02595\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1192607908","title":"GENFLEET-B Shares Surge Following Clinical Trial Acceptance and Positive Analyst Coverage","url":"https://stock-news.laohu8.com/highlight/detail?id=1192607908","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1192607908?lang=en_us&edition=fundamental","pubTime":"2026-05-20 11:30","pubTimestamp":1779247831,"startTime":"0","endTime":"0","summary":"GENFLEET-B (02595) saw its shares rise over 6% during the trading session. At the time of reporting, the stock was up 4.62%, trading at HKD 35.80 with a turnover of HKD 17.952 million. The latest...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0183","BK0028","159938","BK1515","BK0012","09939","BK0276","BK0188","BK1161","BK1574","02595","600369"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1161345000","title":"GENFLEET-B Shares Surge Over 6% Following Clinical Trial Acceptance for Dual-Antibody Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=1161345000","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1161345000?lang=en_us&edition=fundamental","pubTime":"2026-05-20 11:20","pubTimestamp":1779247226,"startTime":"0","endTime":"0","summary":"GENFLEET-B (02595) saw its shares rise more than 6% in morning trading. As of the latest update, the stock was up 5.08%, trading at HK$35.96 with a turnover of HK$16.82 million. The movement follows...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","02595","09939","BK1574","LU1223083913.SGD","159938","BK1161","BK4017","BK4588","CDE","LU1223082196.USD","LU1223082519.USD","BK1515","VXUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636436300","title":"GenFleet GFH375 wins China breakthrough status for KRAS G12D pancreatic cancer therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2636436300","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636436300?lang=en_us&edition=fundamental","pubTime":"2026-05-18 10:25","pubTimestamp":1779071120,"startTime":"0","endTime":"0","summary":"Apricot Capital portfolio company GenFleet Therapeutics secured a Breakthrough Therapy Designation in China for GFH375 as a monotherapy in KRAS G12D-mutant metastatic pancreatic cancer in patients who have received at least one prior systemic therapy.The designation marks the first KRAS G12D inhibitor monotherapy included in China’s BTD list for pancreatic cancer.GenFleet entered a Phase III registrational study for GFH375 monotherapy in 2025, described as the first registrational trial for an oral KRAS G12D inhibitor, run across about 40 sites in China.Partner Verastem Oncology is developing the same asset outside China as VS-7375, which has US FDA Fast Track status for KRAS G12D-mutant pancreatic ductal adenocarcinoma across all lines of therapy.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should n","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260518:nNDL8LMTcn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02595","VSTM","BK4139","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1183200699","title":"Southwest Securities Initiates Coverage on GENFLEET-B, Recommends Active Monitoring for Its Leading Global Pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=1183200699","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1183200699?lang=en_us&edition=fundamental","pubTime":"2026-05-15 17:41","pubTimestamp":1778838084,"startTime":"0","endTime":"0","summary":"Southwest Securities has released a research report initiating coverage on GENFLEET-B (02595), recommending active investor attention. The report highlights the company's strategy of targeting large...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0012","02595","BK0028","BK1515","BK1161","BK0188","BK0183","159938","09939","600369","BK1574","BK0276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1192517748","title":"GenFleet Therapeutics: All 2026 AGM Proposals Cleared; 80% Backing for Expanded Share-Issue Mandate","url":"https://stock-news.laohu8.com/highlight/detail?id=1192517748","media":"Bulletin Express","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1192517748?lang=en_us&edition=fundamental","pubTime":"2026-05-11 18:43","pubTimestamp":1778496215,"startTime":"0","endTime":"0","summary":"GenFleet Therapeutics (GENFLEET-B, 02595) confirmed that shareholders approved every resolution tabled at the 11 May 2026 annual general meeting (AGM), securing both routine business endorsements and...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02595"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634940020","title":"Genfleet Therapeutics shareholders pass AGM resolutions by poll vote","url":"https://stock-news.laohu8.com/highlight/detail?id=2634940020","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634940020?lang=en_us&edition=fundamental","pubTime":"2026-05-11 18:41","pubTimestamp":1778496108,"startTime":"0","endTime":"0","summary":"GenFleet Therapeutics  held its annual general meeting on May 11, 2026.Shareholders adopted 2025 report of board, audited consolidated financial statements, annual report.Reappointment of Ernst & Young as 2026 auditor was authorized, with board empowered to set remuneration and enter related agreements.Amendments were adopted for working rules for independent non-executive directors, related party transaction management system, rules of procedure for shareholders’ meetings, rules of procedure for board of directors.General mandates were granted for repurchase of H shares, issuance of shares, sale or transfer of treasury shares.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genfleet Therapeutics  Inc. published the original content use","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260511:nNDL6rfS2C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02595","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1141681073","title":"Stock Track | ...","url":"https://stock-news.laohu8.com/highlight/detail?id=1141681073","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1141681073?lang=en_us&edition=fundamental","pubTime":"2026-04-29 09:45","pubTimestamp":1777427130,"startTime":"0","endTime":"0","summary":"...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["02595"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1133388661","title":"GENFLEET-B (02595) Clarifies No Connection to Rev Med's Legal Dispute","url":"https://stock-news.laohu8.com/highlight/detail?id=1133388661","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1133388661?lang=en_us&edition=fundamental","pubTime":"2026-04-28 12:40","pubTimestamp":1777351214,"startTime":"0","endTime":"0","summary":"GENFLEET-B (02595) has issued an announcement stating that the company recently noted several reports concerning a letter sent by Revolution Medicines Inc. (\"Rev Med\") to a third-party company...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1515","159938","BK1161","02595","BK1574","09939"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145822667","title":"Stock Track | GenFleet Therapeutics Plummets 11.85% Intraday After Clarification on Patent Disputes","url":"https://stock-news.laohu8.com/highlight/detail?id=1145822667","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1145822667?lang=en_us&edition=fundamental","pubTime":"2026-04-28 12:32","pubTimestamp":1777350767,"startTime":"0","endTime":"0","summary":"GenFleet Therapeutics-B (02595) experienced a significant intraday decline of 11.85% on Tuesday, as the stock plummeted during the trading session.The sharp drop followed the company's clarification...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["02595"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630845326","title":"Genfleet Therapeutics (Shanghai) Inc - States Gfh276 Developed on Independent Proprietary Intellectual Property","url":"https://stock-news.laohu8.com/highlight/detail?id=2630845326","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630845326?lang=en_us&edition=fundamental","pubTime":"2026-04-28 12:29","pubTimestamp":1777350598,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260428:nFWN41A159:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","02595"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630325016","title":"Genfleet Therapeutics (Shanghai) Inc -  All Entities, Products or Disputed Matters Referenced in Revmed's Correspondence  Entirely Unrelated to Co","url":"https://stock-news.laohu8.com/highlight/detail?id=2630325016","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630325016?lang=en_us&edition=fundamental","pubTime":"2026-04-28 12:29","pubTimestamp":1777350598,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260428:nFWN41A159:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02595","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630021325","title":"GenFleet says GFH276 IP independent, not tied to RevMed RAS patent disputes","url":"https://stock-news.laohu8.com/highlight/detail?id=2630021325","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630021325?lang=en_us&edition=fundamental","pubTime":"2026-04-28 12:29","pubTimestamp":1777350595,"startTime":"0","endTime":"0","summary":"GenFleet issued a clarification saying its Pan RAS  inhibitor GFH276 is unrelated to patent or trade secret disputes referenced in correspondence from Revolution Medicines on RAS inhibitors.GenFleet stated GFH276 was developed using independent, proprietary intellectual property, with no exposure to infringement or trade secret risks tied to those disputes.Company highlighted a global patent portfolio for its Pan RAS program, citing publication of a core patent covering GFH276’s compound structure on March 6, 2025.GenFleet said patent protection for that core filing is projected to run through 2044.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genfleet Therapeutics  Inc. published the original content used to generate this news brief","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260428:nNDLb3WJHz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK4139","02595","RVMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145605681","title":"GENFLEET-B Surges Over 7% in Morning Session as Two GFH375/VS-7375 Preclinical Studies Selected for Late-Breaking Research Abstracts","url":"https://stock-news.laohu8.com/highlight/detail?id=1145605681","media":"Deep News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1145605681?lang=en_us&edition=fundamental","pubTime":"2026-04-24 12:05","pubTimestamp":1777003535,"startTime":"0","endTime":"0","summary":"GENFLEET-B (02595) saw its shares rise by 7.34% in morning trading, currently priced at HKD 48.58, with a turnover of HKD 52.61004 million. On April 23, according to an announcement from GENFLEET-B,...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4085","BK1515","159938","BK1161","02595","BK1574","VS","09939"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1181471426","title":"GENFLEET-B Shares Surge Over 4% in Morning Session on Release of Preclinical Data for Pan-RAS Inhibitor GFH276","url":"https://stock-news.laohu8.com/highlight/detail?id=1181471426","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1181471426?lang=en_us&edition=fundamental","pubTime":"2026-04-22 12:02","pubTimestamp":1776830523,"startTime":"0","endTime":"0","summary":"GENFLEET-B (02595) saw its shares rise nearly 6% during the trading session. At the time of writing, the stock was up 4.41%, trading at HK$45.94, with a turnover of HK$21.2173 million. GENFLEET...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1515","159938","09939","02595","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1105867730","title":"Stock Track | Genfleet Therapeutics Soars 5.55% Intraday on Strong Revenue Growth, Buyback Plan, and Breakthrough Therapy Designation","url":"https://stock-news.laohu8.com/highlight/detail?id=1105867730","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1105867730?lang=en_us&edition=fundamental","pubTime":"2026-04-22 11:36","pubTimestamp":1776829001,"startTime":"0","endTime":"0","summary":"Genfleet Therapeutics-B (02595.HK) saw its stock price soar 5.55% during intraday trading on Wednesday, driven by a cluster of positive company-specific developments.The rally follows the company's...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["02595"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1135051908","title":"GenFleet Therapeutics to Seek Shareholder Nod for Share Mandates, Governance Revamp at 11 May 2026 AGM","url":"https://stock-news.laohu8.com/highlight/detail?id=1135051908","media":"Bulletin Express","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1135051908?lang=en_us&edition=fundamental","pubTime":"2026-04-17 23:03","pubTimestamp":1776438192,"startTime":"0","endTime":"0","summary":"GenFleet Therapeutics (Shanghai) Inc. has called its 2025 annual general meeting for 11 May 2026 in Shanghai to vote on a broad slate of corporate and capital-management proposals. Key agenda items...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02595"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1157627828","title":"GenFleet Therapeutics Schedules 11 May 2026 AGM to Approve 2025 Results, Auditor Re-Appointment and Share Buy-Back Mandate","url":"https://stock-news.laohu8.com/highlight/detail?id=1157627828","media":"Bulletin Express","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1157627828?lang=en_us&edition=fundamental","pubTime":"2026-04-17 23:03","pubTimestamp":1776438180,"startTime":"0","endTime":"0","summary":"GenFleet Therapeutics (Shanghai) Inc. will convene its 2026 Annual General Meeting on 11 May 2026 at 10:00 a.m. in the company’s meeting room at Building 73, Lane 1000, Zhangheng Road, Pudong New...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02595"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1113362583","title":"GenFleet Therapeutics Sets 11 May 2026 AGM; Targets 10% Share Buy-back and 20% Issuance Mandates","url":"https://stock-news.laohu8.com/highlight/detail?id=1113362583","media":"Bulletin Express","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1113362583?lang=en_us&edition=fundamental","pubTime":"2026-04-17 23:02","pubTimestamp":1776438176,"startTime":"0","endTime":"0","summary":"GenFleet Therapeutics (Shanghai) Inc. will hold its 2025 Annual General Meeting on 11 May 2026 at 10:00 a.m. in Shanghai. Shareholders will vote on 11 resolutions, covering routine reporting items,...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02595"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628207233","title":"Genfleet Therapeutics announces annual general meeting notice","url":"https://stock-news.laohu8.com/highlight/detail?id=2628207233","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628207233?lang=en_us&edition=fundamental","pubTime":"2026-04-17 22:47","pubTimestamp":1776437226,"startTime":"0","endTime":"0","summary":"GenFleet Therapeutics scheduled 2025 annual general meeting in Shanghai on May 11, 2026.Shareholders set to vote on 2025 board report, audited consolidated financial statements, annual report.Meeting agenda includes 2025-2026 directors’ remuneration package, reappointment of Ernst & Young as 2026 auditor.Special resolutions seek mandates to repurchase up to 10% of issued shares, issue up to 20% of issued shares, including sale or transfer of treasury shares.Proposals also cover amendments to corporate governance systems, including procedures for shareholders’ meetings, board of directors, independent non-executive directors, related party transaction management.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genfleet Therapeutics  Inc.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260417:nNDLb6tsfV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02595"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628520748","title":"Genfleet Therapeutics publishes 2025 annual report","url":"https://stock-news.laohu8.com/highlight/detail?id=2628520748","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628520748?lang=en_us&edition=fundamental","pubTime":"2026-04-17 22:43","pubTimestamp":1776437000,"startTime":"0","endTime":"0","summary":"Genfleet Therapeutics released its 2025 annual report, highlighting progress across its RAS-focused oncology pipeline following its Hong Kong listing on Sept. 19, 2025.Flagship KRAS G12D candidate GFH375 entered world’s first phase III registrational oral KRAS G12D monotherapy trial in Nov. 2025 for metastatic pancreatic cancer.Commercial product fulzerasib, China’s first marketed KRAS G12C inhibitor, secured inclusion in National Reimbursement Drug List in Dec. 2025 with reimbursement effective in 2026.Pipeline expansion continued with Pan RAS inhibitor GFH276 entering clinic in Sept. 2025, while cachexia bispecific antibody GFS202A dosed first patient in March 2025.Genfleet reported steady revenue growth driven by licensing partnerships, supported by cash and bank balances above RMB 2 billion at end-2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-gener","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260417:nNDL1HrT1D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02595"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":1,"totalSize":73,"code":"91000000","status":"200"}]}}